CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04138875
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:36.258509+00:00
Published At: 2022-06-23T00:00:00+00:00
Record Updated At: 2022-06-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["PTLD", "Lymphoid Tumor", "Hematopoietic/Lymphoid Cancer", "Plasmacytic Hyperplasia PTLD", "Infectious Mononucleosis", "Florid Follicular Hyperplasia PTLD", "Polymorphic PTLD", "Monomorphic PTLD", "Classical Hodgkin Lymphoma Type PTLD"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-06-23"
protocolSection.identificationModule.nctId: "NCT04138875"
protocolSection.identificationModule.officialTitle: "A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed."
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.